Amlodipine/candesartan cilexetil - CJ HealthCare

Drug Profile

Amlodipine/candesartan cilexetil - CJ HealthCare

Alternative Names: Amlodipine besylate/candesartan cilexetil; CJ 30059

Latest Information Update: 20 Mar 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator CJ HealthCare
  • Class Antihypertensives; Benzimidazoles; Biphenyl compounds; Dihydropyridines; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Essential hypertension
  • Phase I Angina pectoris

Most Recent Events

  • 01 Oct 2014 CJ Healthcare initiates enrolment in a phase III trial for Essential hypertension in South Korea (PO) (NCT02368665)
  • 01 Oct 2014 Phase-III clinical trials in Essential hypertension in South Korea (PO) (NCT02368652)
  • 01 Jun 2014 Phase-I clinical trials in Angina pectoris (healthy volunteers) in South Korea (PO) (NCT02173912)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top